EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension

• Status: Completed
• Trial end date: 2018-06-29
• Target enrollment: 0
• Participant gender: All

Summary

In accordance with the regulatory guidance this registry has been designed to collect information about the long-term safety of Adempas in real clinical practice outside the regulated environment of a controlled clinical study.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Riociguat

Criteria

Inclusion Criteria:

• Female and male patients who start or are on treatment with Adempas

• Written informed consent

Exclusion Criteria:

• Patients currently participating in an interventional clinical trial